Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS

Journal of Chromatographic Science

Volumn 48, Issue 5, 2010, Pages 375-381

  Shah, Hiten J ^a,b   Subbaiah, Gunta ^a   Patel, Dasharath M ^a   Suhagia, Bhanubhai N ^c   Patel, Chhagan N ^b  

^a Torrent Pharmaceuticals Ltd   (India)

^b Shri Sarvajanik Pharmacy College   (India)

^c L M COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953076559     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.5.375     Document Type: Article

References (34)

1. A. Fitton and K.L. Goa. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 50: 691-713 (1995).
2. S.C. Schachter, E. Leppik, F. Matsuo, J.A. Messenheimer, E. Faught, E.L. Moore, and M.E. Risner. Lamotrigine: a six month, placebo-controlled, safety and tolerance study. J. Epilepsy 8: 201-209 (1995).
3. J. Messenheimer, R. Ramsay, L. Willmore, R. Leroy, J. Zielinski, R. Mattson, J. Pellock, A. Valakas, G. Woulbe, and M. Risner. Lamotrigine therapy for partial seizures: a multicenter placebo-controlled, double-blind cross-over trial. Epilepsia 35: 113-121 (1994).
4. G. Chang, B. Vasquez, F. Gilliam, J.C. Sackellares, P. Burns, M. Risner, and G.D. Rudd. Lamictal (lamotrigine) monotherapy is an effective treatment for partial seizures (abstract). Neurology 48: A335 (1997).
5. M. Brodie, A. Richens, and A. Yuen. Lamotrigine/carbamazepine, monotherapy trial group: double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345: 476-479 (1995).
6. F. Matsuo, D. Bergen, E. Faught, J.A. Messenheimer, A.T. Dren, G.D. Rudd, and C.G. Lineberry. Lamotrigine protocol 05 clinical trial group: placebo-controlled study of the efficacy and safety of lamotrigine in patient with partial seizures. Neurology 43: 2284-2291 (1993).
7. E.G.Mcgeer and S.G. Zhu. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci. Lett. 112: 348-351(1990).
8. J. Rataud, F. Debarnot, V. Mary, J. Pratt, and J.M. Stutzmann. Comparative study of voltage sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci. Lett. 172: 19-23 (1994).
9. S.E. Smith and B.S. Meldrum. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 26: 117-121 (1995).
10. R.C. Crumrine, K. Bergstrand, A.T. Cooper, W.L. Faison, and B.R. Cooper. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 28: 2230-2236 (1997).
11. R.P. Wiard, M.C. Dickerson, O. Beek, R. Norton, and B.R. Cooper. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model cerebral ischemia. Stocke 26: 446-472 (1995).
12. Physical Desk Reference 61: 1481-1490 (2007).
13. A.F. Cohen, G.S. Land, D.D. Breimer, W.C. Yuen, C. Winton, and A.W. Peck. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42: 68-73 (1987).
14. Peck AW. Clinical Pharmacology of lamotrigine. Epilepsia 32(2): S9-S12 (1991).
15. R.D.C. Elwes and C.D. Binnie. Clinical pharmacokinetics of newer antiepileptic drugs: lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin. Pharmacokinet. 30: 403-415 (1996).
16. G.S. Elizabeth, R.L. Darla, A.V. Mohamed, and D.K. Matthew. Simultaneous determination of lamotrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 21: 225-228 (2007).
17. T.A.C. Vermeij and P.M. Edelbroek. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solidphase extraction. J. Chromatogr. B 857: 40-46 (2007).
18. G. Christine and H. Ekkehard. Development of simple column-switching high performance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine and 10- monohydroxycarbazepine (MHD). J. Chromatogr. B 854: 338-344 (2007).
19. C. Manuela, B. Monica, C. Erica, C. Carmina, A. Fiorenzo, R. Roberto, and B. Agostino. Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J. Chromatogr. B 828: 113-117 (2005).
20. L.C. Ching, H.C. Chen, and Y.P.U. Oliver. Determination of lamotrigine in small volume of plasma by high-performance liquid chromatography. J. Chromatogr. B 817: 199-206 (2005).
21. K.M. Patil and S.L. Bodhankar. Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J. Pharm. Biomed. Anal. 39: 181-186 (2005).
22. K.M. Matar, P.J. Nicholls, S.A. Bawazir, M.I. Al-Hassan, and A. Tekle. A rapid liquid chromatographic method for the determination of lamotrigine in plasma. J. Pharm. Biomed. Anal. 17: 525-531 (1998).
23. F. Eva, E.A. Sofie, and B. Olof. Liquid chromatographic determination of plasma lamotrigine in pediatric samples. J. Pharm. Biomed. Anal. 14: 755-758 (1996).
24. O. Beck, I. Ohman, and H.K. Nordgren. Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther. Drug Monit. 28(5): 603-607 (2006).
25. Z. Shaolian, S. Qi, T. Yong, and N. Weng. Critical review of development, validation, and transfer for high throughput bioanalytical LC-MS-MS methods. Curr. Pharm Anal. 1: 3-14 (2005).
26. L. Yang, N. Wu, and P.J. Rudewicz. Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support. J. Chromatogr. A 926: 43-55 (2001).
27. W.A. Korfmacher, J. Veals, K.D. Meynell, X.P. Zhang, G. Tucker, K.A. Cox, and C.C. Lin. Demonstration of the capabilities of a parallel high performance liquid chromatography tandem mass spectrometry system for use in the analysis of drug discovery plasma samples. Rapid Commun. Mass Spectrom. 13: 1991-1998 (1999).
28. C.K. Van Pelt, T.N. Corso, G.A. Schultz, S. Lowes, and J. Henion. A Four-Column Parallel Chromatography System for Isocratic or Gradient LC/MS Analyses. Anal. Chem. 73: 582-588 (2001).
29. R.C. King, C.M. Stein, and D.J. Magiera, J Brann. Description and validation of a staggered parallel high performance liquid chromatography system for good laboratory practice level quantitative analysis by liquid chromatography/tandem mass spectrometry. Rapid Commun.Mass Spectrom. 16: 43-52 (2002).
30. R. Oertel, K. Richter, J. Fauler, and W. Kirch. Increasing sample throughput in pharmacological studies by using dual-column liquid chromatography with tandem mass spectrometry. J. Chromatogr. A 948: 187-192 (2002).
31. M. Jemal, M. Huang, Y.Mao, D.Whigan, andM.L. Powell. Increased throughput in quantitative bioanalysis using parallel-column liquid chromatography with mass spectrometric detection. Rapid Commun. Mass Spectrom. 15: 994-999 (2001).
32. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC-MS-MS. Anal. Chem. 75: 3019-3030 (2003).
33. Guidance for Industry: Bioanalytical Method validation, 525 U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM). May 2001.
34. FDA Guidance for Industry: Bioavailability Studies for Orally Administered Drug- Products-General Considerations, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), 2000.